Wegovy® (Semaglutide) Weight Management Therapy

Overview

Wegovy® (semaglutide) is a prescription GLP-1 receptor agonist approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in certain adults. It is used as part of a comprehensive, clinician-guided medical weight management plan that includes nutrition, physical activity, and ongoing medical supervision.

Semaglutide works by mimicking a naturally occurring hormone involved in appetite regulation, digestion, and metabolic processes. Treatment decisions are individualized and made by a licensed medical provider following a clinical evaluation.

How Wegovy® (Semaglutide) Works

Semaglutide supports medical weight management through several physiological mechanisms, including:

Acting on appetite regulation centers in the brain to reduce hunger signals
Slowing gastric emptying to promote a feeling of fullness
Supporting blood sugar regulation and metabolic balance

Responses to treatment vary by individual and are monitored as part of ongoing medical care.

Who May Be a Candidate?

You may be a candidate for semaglutide therapy if you:

Have obesity or overweight with related health conditions
Have not achieved desired outcomes with lifestyle changes alone
Are seeking a clinician-guided medical weight management option
Are able to participate in ongoing monitoring and follow-up care

Wegovy® is not appropriate for everyone. A licensed medical provider will determine candidacy following a comprehensive health assessment.

Indications for Use

Wegovy® is FDA-approved for chronic weight management in adults with obesity or overweight who have weight-related health conditions. It is intended to be used alongside lifestyle modifications and medical monitoring.

Eligibility for Wegovy® is determined by a licensed medical provider based on medical history, current health conditions, and individual treatment goals. Not all patients are appropriate candidates, and medical evaluation is required prior to prescribing.

Compound Semaglutide Options

In certain situations, a licensed medical provider may discuss compounded semaglutide as an alternative option when FDA-approved medications are unavailable or not appropriate for a patient’s specific circumstances.

Compounded medications are prepared by licensed U.S. compounding pharmacies based on a provider’s prescription. Compounded semaglutide is not FDA-approved and does not undergo the same review process as commercially manufactured medications.

The decision to use compounded medication is made on an individual basis following a thorough discussion of risks, benefits, and alternatives.

Important Safety Information

Wegovy® may not be appropriate for all individuals. Certain medical conditions, medications, or health factors may affect eligibility. Wegovy® is not recommended for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

A licensed medical provider will review medical history and discuss potential risks and considerations prior to prescribing.

Wegovy® is a registered trademark of Novo Nordisk
Bluegrass Telehealth Lexington is independently owned and not affiliated with Novo Nordisk.